Effect of N_Acetylcysteine on Liver Functions in Donors in Living Liver Transplantation

Effect of N_Acetylcysteine on Liver Functions in Donors in Living Donor Liver Transplantation

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03634566

Enrollment

Registered

2018-08-16

Start date

2018-04-01

Completion date

2019-04-01

Last updated

2020-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplant; Complications

Brief summary

our practice for the past 10 years we have noticed a transitional impairment of liver function (elevated liver enzymes, total and direct bilirubin, and elevated serum lactate levels) following donors' liver resection. Several drugs have been investigation on liver regeneration , proven benefit of N-Acetylcysteine (NAC) on rats with steatohpatitis

Interventions

DRUGN-Acetylecysteine

N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days

DRUGPlacebo

Ringer acetate continuous infusion at the same rate for 2 days.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* ASA I or II donors * healthy adult

Exclusion criteria

* kidney, liver disease * any contraindications for organ donation

Design outcomes

Primary

Measure	Time frame
Serum lactate	24 hours postoperative

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026